SG11202004954YA - Methods for treating gaucher disease - Google Patents
Methods for treating gaucher diseaseInfo
- Publication number
- SG11202004954YA SG11202004954YA SG11202004954YA SG11202004954YA SG11202004954YA SG 11202004954Y A SG11202004954Y A SG 11202004954YA SG 11202004954Y A SG11202004954Y A SG 11202004954YA SG 11202004954Y A SG11202004954Y A SG 11202004954YA SG 11202004954Y A SG11202004954Y A SG 11202004954YA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- gaucher disease
- treating gaucher
- treating
- disease
- Prior art date
Links
- 208000015872 Gaucher disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762599467P | 2017-12-15 | 2017-12-15 | |
| PCT/US2018/065423 WO2019118707A1 (en) | 2017-12-15 | 2018-12-13 | Methods for treating gaucher disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202004954YA true SG11202004954YA (en) | 2020-06-29 |
Family
ID=65023988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202004954YA SG11202004954YA (en) | 2017-12-15 | 2018-12-13 | Methods for treating gaucher disease |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10888544B2 (en) |
| EP (1) | EP3723809A1 (en) |
| JP (2) | JP2021506789A (en) |
| KR (1) | KR20200100697A (en) |
| CN (2) | CN116139130A (en) |
| AU (1) | AU2018386182B2 (en) |
| BR (1) | BR112020011056A2 (en) |
| CA (1) | CA3083663A1 (en) |
| CO (1) | CO2020008319A2 (en) |
| IL (1) | IL275091B1 (en) |
| MX (1) | MX2020006272A (en) |
| SG (1) | SG11202004954YA (en) |
| WO (1) | WO2019118707A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113893346B (en) * | 2020-06-22 | 2022-11-18 | 四川大学华西医院 | Application of GCS inhibitor in preparation of drug for treating cocaine addiction |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997010817A1 (en) | 1995-09-20 | 1997-03-27 | The Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| ES2395463T3 (en) | 2001-07-16 | 2013-02-15 | Genzyme Corporation | An N-acylphingosine glucosyltransferase inhibitor |
| SI3133070T1 (en) * | 2009-11-27 | 2019-11-29 | Genzyme Corp | Eliglustat (genz 112638) as inhibitor of glucosylceramide synthase for use in a method of treating fabry's or gaucher's disease, the method comprising adjusting the individual therapeutical dose to the p-450 metabolism of the patient |
-
2018
- 2018-12-13 JP JP2020532586A patent/JP2021506789A/en active Pending
- 2018-12-13 EP EP18834099.6A patent/EP3723809A1/en active Pending
- 2018-12-13 SG SG11202004954YA patent/SG11202004954YA/en unknown
- 2018-12-13 KR KR1020207020313A patent/KR20200100697A/en not_active Application Discontinuation
- 2018-12-13 MX MX2020006272A patent/MX2020006272A/en unknown
- 2018-12-13 BR BR112020011056-6A patent/BR112020011056A2/en unknown
- 2018-12-13 CN CN202211533196.1A patent/CN116139130A/en active Pending
- 2018-12-13 CN CN201880080657.XA patent/CN111479591A/en active Pending
- 2018-12-13 IL IL275091A patent/IL275091B1/en unknown
- 2018-12-13 US US16/219,064 patent/US10888544B2/en active Active
- 2018-12-13 CA CA3083663A patent/CA3083663A1/en active Pending
- 2018-12-13 WO PCT/US2018/065423 patent/WO2019118707A1/en unknown
- 2018-12-13 AU AU2018386182A patent/AU2018386182B2/en active Active
-
2020
- 2020-07-06 CO CONC2020/0008319A patent/CO2020008319A2/en unknown
- 2020-12-07 US US17/113,633 patent/US20210330633A1/en not_active Abandoned
-
2023
- 2023-09-08 JP JP2023145812A patent/JP2023171774A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3723809A1 (en) | 2020-10-21 |
| KR20200100697A (en) | 2020-08-26 |
| CN111479591A (en) | 2020-07-31 |
| JP2023171774A (en) | 2023-12-05 |
| CO2020008319A2 (en) | 2020-10-30 |
| CN116139130A (en) | 2023-05-23 |
| MX2020006272A (en) | 2020-09-14 |
| IL275091A (en) | 2020-07-30 |
| CA3083663A1 (en) | 2019-06-20 |
| JP2021506789A (en) | 2021-02-22 |
| US10888544B2 (en) | 2021-01-12 |
| AU2018386182B2 (en) | 2024-03-28 |
| BR112020011056A2 (en) | 2020-11-17 |
| US20210330633A1 (en) | 2021-10-28 |
| RU2020119588A3 (en) | 2022-04-11 |
| RU2020119588A (en) | 2022-01-17 |
| AU2018386182A1 (en) | 2020-07-02 |
| IL275091B1 (en) | 2024-05-01 |
| US20190183844A1 (en) | 2019-06-20 |
| WO2019118707A1 (en) | 2019-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281633A (en) | Methods for treating huntington's disease | |
| ZA201705673B (en) | Methods for treating skin | |
| IL269371A (en) | Treatment methods | |
| IL279308A (en) | Methods for treating hepcidin-mediated disorders | |
| HK1250752A1 (en) | Methods for treating myeloproliferative disorders | |
| IL278247B (en) | Mct4 inhibitors for treating disease | |
| HK1244217A1 (en) | Methods for treating proteinopathies | |
| IL266530A (en) | Treatment for fibrosis | |
| HK1253238A1 (en) | Gls1 inhibitors for treating disease | |
| PT3393468T (en) | Methods for treating immunodeficiency disease | |
| GB2567616B (en) | Treatment method | |
| PT3164394T (en) | Gls1 inhibitors for treating disease | |
| GB2571601B (en) | Treatment method | |
| IL276577A (en) | Methods for treating cardiac injury | |
| IL252904A0 (en) | Methods and agents for treating disease | |
| SG11202001806TA (en) | Treatment method | |
| IL270867A (en) | Treatment method | |
| SG11202003127WA (en) | Methods for treating lymphomas | |
| IL275091A (en) | Methods for treating gaucher disease | |
| IL254336A0 (en) | Novel treatment method | |
| IL272977A (en) | Method for treating tnfα-related disease | |
| ZA201607027B (en) | Method for treating or enhancing muscle tissue | |
| GB201700099D0 (en) | Therapeutic method | |
| GB201414611D0 (en) | Method for processing tissue |